Iovance Biotherapeutics, Inc. IOVA Non Cash Stock Based Compensation Included In Cost Of Sales
Non Cash Stock Based Compensation Included In Cost Of Sales at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept iova:NonCashStockBasedCompensationIncludedInCostOfSales.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s non cash stock based compensation included in cost of sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s non cash stock based compensation included in cost of sales?
- Iovance Biotherapeutics, Inc. (IOVA) reported non cash stock based compensation included in cost of sales of $1.02M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s non cash stock based compensation included in cost of sales changed year-over-year?
- Iovance Biotherapeutics, Inc.'s non cash stock based compensation included in cost of sales decreased by 57.9% year-over-year, from $2.42M to $1.02M.
- What does non cash stock based compensation included in cost of sales mean?
- This represents the portion of stock-based compensation expense allocated specifically to the cost of goods sold or services rendered. It reflects the non-cash cost of equity-based incentives granted to personnel directly involved in the production or delivery process. Tracking this helps investors understand the non-cash component embedded within the company's gross margin structure.